RA
VRTX icon

RiverTree Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

RiverTree Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-753
Closed -$218K – 47
2022
Q3 		$218K Buy
+753
New +$217K 0.18% 24

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RiverTree Advisors's VRTX Position: Q4 2022 in Review

RiverTree Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 753 shares — an estimated $218K sold.

RiverTree Advisors first reported a position in VRTX in Q3 2022 and held it in 1 quarter. The position peaked at $218K in Q3 2022. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

  • RiverTree Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • RiverTree Advisors sold 753 Vertex Pharmaceuticals shares in Q4 2022, an estimated $218K.
  • RiverTree Advisors first reported a position in Vertex Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • RiverTree Advisors's Vertex Pharmaceuticals position peaked at $218K in Q3 2022.
  • 1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on RiverTree Advisors's 13F filing for Q4 2022, filed 3 Feb 2023.